These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 16312316

  • 1. Piperacillin + tazobactam: fixed ratio versus fixed concentration synergism studies.
    Cullmann W, Stieglitz M.
    J Chemother; 1989 Jul; 1(4 Suppl):85-6. PubMed ID: 16312316
    [No Abstract] [Full Text] [Related]

  • 2. Synergistic activity of piperacillin: YTR-830H combinations in vitro and in vivo.
    Kuck NA, Petersen PJ, Weiss WJ, Jacobus NV, Testa RT, Tally FP.
    J Chemother; 1989 Jul; 1(4 Suppl):105-6. PubMed ID: 16312325
    [No Abstract] [Full Text] [Related]

  • 3. ILSMRs (intensifier of beta-lactam-susceptibility in methicillin-resistant Staphylococcus aureus) from Tara [Caesalpinia spinosa (Molina) Kuntze].
    Kondo K, Takaishi Y, Shibata H, Higuti T.
    Phytomedicine; 2006 Feb; 13(3):209-12. PubMed ID: 16428032
    [Abstract] [Full Text] [Related]

  • 4. In vitro activity of YTR-830H in combination with beta-lactamase unstable beta-lactams.
    Chin NX, Neu HC.
    J Chemother; 1989 Jul; 1(4 Suppl):90-2. PubMed ID: 16312319
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Polyamine effects on antibiotic susceptibility in bacteria.
    Kwon DH, Lu CD.
    Antimicrob Agents Chemother; 2007 Jun; 51(6):2070-7. PubMed ID: 17438056
    [Abstract] [Full Text] [Related]

  • 7. In-vitro evaluation of "piperacillin and tazobactum" combination in a tertiary-care hospital--a preliminary study.
    Kumari N, Mohapatra TM, Rai A, Bhattacharya SK.
    Indian J Pathol Microbiol; 2006 Jan; 49(1):57-8. PubMed ID: 16625981
    [No Abstract] [Full Text] [Related]

  • 8. Comparison of in vitro activities of levofloxacin, ciprofloxacin, ceftazidime, cefepime, imipenem, and piperacillin-tazobactam against aerobic bacterial pathogens from patients with nosocomial infections.
    Huang SS, Lee SC, Lee N, See LC, Tsai MH, Shieh WB.
    J Microbiol Immunol Infect; 2007 Apr; 40(2):134-40. PubMed ID: 17446961
    [Abstract] [Full Text] [Related]

  • 9. In vitro activities of various piperacillin and sulbactam combinations against bacterial pathogens isolated from Intensive Care Units in Taiwan: SMART 2004 programme data.
    Hung MN, Hsueh PR, Chang HT, Lee WS, Chou MY, Chen IS, Wang JH, Lin CF, Shyr JM, Ko WC, Wu JJ, Liu YC, Huang WK, Teng LJ, Liu CY, Luh KT.
    Int J Antimicrob Agents; 2007 Feb; 29(2):145-52. PubMed ID: 16815690
    [Abstract] [Full Text] [Related]

  • 10. N-thiolated 2-oxazolidinones: a new family of antibacterial agents for methicillin-resistant Staphylococcus aureus and Bacillus anthracis.
    Mishra RK, Revell KD, Coates CM, Turos E, Dickey S, Lim DV.
    Bioorg Med Chem Lett; 2006 Apr 15; 16(8):2081-3. PubMed ID: 16464583
    [Abstract] [Full Text] [Related]

  • 11. [Infection in neutropenic cancer patients--etiology, microbiological diagnostics, treatment].
    Durnaá B, Dzierzanowska D.
    Wiad Lek; 2006 Apr 15; 59(7-8):506-11. PubMed ID: 17209349
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of the in vitro activity of ertapenem and nine other comparator agents against 337 anaerobic bacteria.
    Behra-Miellet J, Dubreuil L, Calvet L.
    Int J Antimicrob Agents; 2006 Jul 15; 28(1):25-35. PubMed ID: 16757152
    [Abstract] [Full Text] [Related]

  • 13. [Role of Ph-SA in enhancing bactericidal activity of beta-lactam antibiotics].
    Tang XY, Zhang J, Guo L, Qiu XQ.
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2006 Jan 15; 37(1):48-51. PubMed ID: 16468640
    [Abstract] [Full Text] [Related]

  • 14. Antibacterial activity of allicin alone and in combination with beta-lactams against Staphylococcus spp. and Pseudomonas aeruginosa.
    Cai Y, Wang R, Pei F, Liang BB.
    J Antibiot (Tokyo); 2007 May 15; 60(5):335-8. PubMed ID: 17551215
    [Abstract] [Full Text] [Related]

  • 15. Activity of ertapenem and comparators against recent clinical isolates from intra-abdominal abscesses (SMART 2009).
    Hawser SP.
    J Infect; 2011 Jun 15; 62(6):496-7. PubMed ID: 21458487
    [No Abstract] [Full Text] [Related]

  • 16. Comparative activity of beta-lactamase inhibitors combined with beta-lactams against antibiotic-resistant enterobacter.
    Tejedor-Junco MT, Gonzalez-Martin M, Lupiola PA, Santana OE, Lopez-Orge RH, Gonzalez-Lama Z.
    J Chemother; 1989 Jul 15; 1(4 Suppl):346-8. PubMed ID: 16312432
    [No Abstract] [Full Text] [Related]

  • 17. In vitro efficacy of ceftriaxone/sulbactam against Escherichia coli isolates producing CTX-M-15 extended-spectrum beta-lactamase.
    Shahid M, Singhai M, Malik A, Shukla I, Khan HM, Shujatullah F, Tahira F.
    J Antimicrob Chemother; 2007 Jul 15; 60(1):187-8. PubMed ID: 17491002
    [No Abstract] [Full Text] [Related]

  • 18. Irreproducible piperacillin/tazobactam minimum inhibitory concentrations in microdilution tests with Escherichia coli strains.
    Thomson KS, Black J, Moland ES, Reuben J, Wiles T, Brasso W.
    Int J Antimicrob Agents; 2008 Jan 15; 31(1):83-5. PubMed ID: 17996426
    [No Abstract] [Full Text] [Related]

  • 19. Anti-MRSA beta-lactams in development.
    Page MG.
    Curr Opin Pharmacol; 2006 Oct 15; 6(5):480-5. PubMed ID: 16899405
    [Abstract] [Full Text] [Related]

  • 20. In vitro study of the antibacterial activity of cefotetan compared with piperacillin and ceftriaxone against bacterial strains isolated from pathological material of hospital patients.
    Gatti M, Varoli O, Piscolla F.
    J Chemother; 1989 Jul 15; 1(4 Suppl):103-4. PubMed ID: 16312324
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.